Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Vanderbilt-Ingram Cancer Center
University of California, San Francisco
H. Lee Moffitt Cancer Center and Research Institute
Northside Hospital, Inc.